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Abstract
Background: Postpartum hemorrhage remains the leading cause of maternal mortality worldwide. Administration
of uterotonics during the third stage of labor is a simple and well established intervention that can significantly
decrease the development of postpartum hemorrhage. Little is known about the use of prophylactic uterotonics in
peripheral health centers, where the majority of normal deliveries occur. The purpose of this study is to assess
health provider current practices and determinants to the use of prophylactic uterotonics in Sierra Leone, a country
with one of the highest maternal mortality ratios worldwide.
Methods: This is a mixed methods study using descriptive cross-sectional survey and qualitative interviews in
community health facilities in Freetown, Sierra Leone following a comprehensive training on postpartum
hemorrhage. Facilities and providers were surveyed between May and June 2014. Qualitative methods were used
to identify barriers and facilitators to the use of prophylactic uterotonics.
Results: A total of 134 providers were surveyed at 39 periphreal health facilities. Thirteen facilities (39 %) reported
an inconsistent supply of oxytocin. The majority of facilities (64 %) stored oxytocin at room temperature. Provider
level, in-service training, and leadership role were significantly associated with prophylactic uterotonic use. Overall,
62 % of providers reported routine use. Midwives were most likely to routinely administer uterotonics (93 %),
followed by community health officers/assistants (78 %), maternal and child health aides (56 %), and state-enrolled
community health nurses (52 %). Of the providers who received in-service training, 67 % reported routine use; of
those with no in-service training, 42 % reported routine use. Qualitative analysis revealed that facility protocols,
widespread availability, and provider perception of utility facilitated routine use. Common barriers reported included
inconsistent supply of uterotonics, lack of knowledge regarding timely administration, and provider attitude
regarding utility of uterotonics following normal deliveries.
Conclusion: There is considerable room for improvement in availability and administration of prophylactic
uterotonics. Understanding barriers to routine use may aid in developing multifaceted pre-service and in-service
training interventions designed to improve routine intrapartum care.
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Background
Postpartum hemorrhage (PPH) is the most common
cause of maternal mortality and morbidity worldwide,
with the majority of PPH-related deaths occurring in
low-income countries [1–3]. Active management of the
third stage of labor (AMTSL) is a well-established proto-
col that has been shown to significantly reduce the inci-
dence of PPH [4, 5]. AMTSL consists of administration
of a prophylactic uterotonic after delivery of the new-
born, fundal massage, delayed cord clamping and con-
trolled cord traction. The initial studies evaluating the
efficacy of AMTSL studied these components as a pack-
age. Although there is strong evidence to recommend
the use of prophylactic uterotonic for the prevention of
PPH, the relative importance of controlled cord traction
and fundal massage is uncertain [6, 7]. Based on this,
the International Federation of Gynecologists and Ob-
stetricians (FIGO) and the World Health Organization
(WHO) recommend routine use of uterotonics to pre-
vent PPH [8, 9].
Despite strong evidence supporting the effectiveness of
these guidelines, there remains significant inter-country
variation in rates of AMTSL uptake. A WHO cross-
sectional survey of 15 university-based obstetric cen-
ters in both developing and developed countries
found low observed use of AMTSL, occurring on
average in only 25 % of deliveries [10]. Other studies
investigating both AMTSL practices and interventions
targeted at improving AMTSL adherence in the hos-
pital setting have also found low rates of knowledge
and application [11–14].
Most research has understandably focused on high-
volume facilities or complicated deliveries; however, little
is known about AMTSL practices in primary health fa-
cilities in particularly low income countries, where nor-
mal uncomplicated deliveries are encouraged [15]. These
facilities are fundamentally different from hospitals in
that they employ lower-skilled providers, have limited
access to health information, and have fewer resources
to manage the consequence of PPH. However, given the
role of preventive practices, understanding provider ad-
herence to interventions that prevent PPH at these facil-
ities can provide insight into opportunities for improving
routine intrapartum care – a cornerstone strategy for
addressing maternal mortality [16].
The purpose of this study is to gain further insight
into provider use of prophylactic uterotonics following a
comprehensive PPH-training package in Freetown, Sierra
Leone. We sought to understand the personal practice
of prophylactic uterotonic administration in providers
conducting routine deliveries. Furthermore, we sought
to understand if factors such as in- service AMTSL
training, provider cadre, and leadership positions were
associated with the routine use of uterotonics. In addition,
qualitative methods were used to identify facilitators and
barriers to routine use of prophylactic uterotonics.
Methods
In December 2013, Massachusetts General Hospital in
conjunction with the Sierra Leone Ministry of Health
conducted a total of eight three-hour workshops on a
PPH in-service training called Every Second Matters for
Mothers and Babies – Uterine Balloon Tamponade
(ESM-UBT). The training components of ESM-UBT in-
cluded AMTSL (administration of 10 IU oxytocin IM or
IV, fundal massage, delayed cord clamping and con-
trolled cord traction), basic PPH management, and the
use of condom-catheter uterine balloon tamponade
(UBT) as a second-line treatment for uncontrolled PPH
[17]. Two representatives from each of 46 peripheral
health facilities – usually a facility head and an experi-
enced midwife – were asked to attend this session and
subsequently disseminate the knowledge to all members
of the facility who are involved in conducting deliveries.
Following the central training, these representatives –
referred to as “UBT champions” - were contacted via
phone to ensure that all members of the facility were
trained. Each facility was provided with two PPH instruc-
tion manuals, a pictorial wall chart, and condom-catheter
UBT kits. By March 2014, all of the original facility repre-
sentatives reported that all members of their facility had
been trained.
This was a descriptive cross-sectional survey of re-
ported uterotonic use during the third stage of labor for
providers working in peripheral health care facilities.
This survey was embedded within a larger qualitative
study assessing facilitators and barriers to uptake of the
ESM-UBT training package (results reported separately).
During May – June 2014, approximately 6 months after
the central training session, a survey was conducted at
39 of the 42 (92.9 %) peripheral health facilities that
attended the initial central training. Three facilities were
not visited because of difficult terrain.
At each facility, information regarding the availability
and storage of uterotonics was obtained from facility or
maternity heads. Since oxytocin is the primary utero-
tonic used and freely distributed by the Sierra Leone
government, providers were specifically asked if they
had a consistent supply of oxytocin available at their fa-
cility. The heads of the facility were then asked to iden-
tify all members of the facility who conduct deliveries on
that particular shift. All providers who conduct deliveries
in primary health facilities in Sierra Leone are authorized
to use oxytocin during the third stage of labor per the
Sierra Leone national protocol for the prevention and
treatment of PPH. Each provider was asked general
questions about their professional training, in-service
training in PPH (including AMTSL), years of experience,
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and delivery volume. Providers were then asked about
their personal practice of managing the third stage of
labor during vaginal deliveries. Qualitative interviews
were conducted to capture provider practices, attitudes,
and perceived barriers to routine use of prophylactic
uterotonics. Verbal informed consent was obtained from
all participants. All data were recorded and entered into
a Microsoft Excel spreadsheet. Clinical results are re-
ported as mean ± SEM. Analyses between groups for sta-
tistically significant differences in categorical data were
performed with the Fisher’s Exact and Fisher-Freeman-
Halton Tests. Student’s t-tests were used to assess differ-
ences among groups with continuous variables (R ver-
sion 3.1.1).
Ethical approval for this study was obtained from the
Partners Healthcare Human Research Committee (12/
18/2013 protocol#: 2012P002112/MGH) and Sierra
Leone Ministry of Health and Sanitation (05/12/2014).
Results
A total of 134 providers were surveyed at 39 study sites
(1–8 interviews per site). Table 1 shows the characteris-
tics of health facilities, including average delivery vol-
ume, oxytocin availability, and oxytocin storage. The
majority of facilities (62 %) were CHCs, followed by
CHPs (26 %), and MCHPs (13 %). Oxytocin was most
consistently available at MCHPs (80 %), followed by
CHP (60 %), and CHCs (58 %). Fifteen facilities (44 %)
reported shortages of oxytocin. The majority of facilities
(64 %) reported storing oxytocin at room temperature.
Table 2 shows the characteristics of providers inter-
viewed. Providers reported conducting between 1 and
100 deliveries per month with a mean (SD) of 20 (19.2)
deliveries per month. Their experience ranged from
6 months to 32 years, with a mean (SD) of 7.2 (6.7)
years. The majority of respondents was female (90 %).
MCHAs (51 %) and SECHNs (25 %) accounted for the
majority of respondents. Thirteen providers (21 %) held
administrative positions – either head of facility or ma-
ternity ward. The majority of providers (77 %) received
targeted training in AMTSL since their professional
training.
When providers were asked about their management
of the third stage of labor, 83 (62 %) of the 134 providers
reported that they routinely give prophylactic uterotonics.
With the exception of one provider who used misoprostol,
all providers who reported uterotonic use reported using
oxytocin. The relationship between provider characteris-
tics and reported use of uterotonics is outlined in Table 3.
Provider level, in-service training, leadership roles, and
years of experience were significantly associated with re-
ported use of uterotonics (p < 0.05). Midwives were most
likely to administer oxytocin (93 %), followed by CHO/
CHA (78 %), MCHAs (56 %), and SECHNs (53 %). Pro-
viders who received a variation of in-service training were
more likely to report administration of uterotonics that
those who did not (p < 0.01). Of the 103 providers who
had in-service training, 69 (67 %) gave uterotonics. Less
than half (42 %) of the 31 providers who did not receive
in-service training administered uterotonics during the
third stage of labor. Providers who administered utero-
tonics on average had 8.5 years of experience (SEM 0.87)
compared with those who did not report using utero-
tonics, who had 5.1 (SEM 0.43) years of experience.
Table 1 Characteristics of health facilities
Facility
type
(n = 39)
Average number
of deliveries in
facility/month
Oxytocin
availability
(% always available)
Oxytocin
storage
(% stored in fridge)
MCHP (n = 5) 21 4 (80 %) 0 (0.0 %)
CHP (n = 10) 31 6 (60 %) 2 (20 %)
CHC (n = 24) 50 14 (58 %) 11 (46 %)
CHP community health post, MCHP maternal and child health post, CHC
community health center
Table 2 Characteristics of obstetric providers interviewed
Characteristics Number Percent (%)
Experience (years)
0-9 97 72
10-19 27 20
20-29 6 5
>30 4 3
Gender
Male 13 10
Female 121 90
Cadre
Midwife 14 11
SECHN 34 25
MCHA 68 51
CHO/CHA 18 13
Leadership*
Yes 28
No 106 21
AMTSL training 79
In-service AMTSL training 103 77
No in-service training 31 23
Provider average deliveries/month
1-19 81 60
20-39 32 24
40-59 13 10
60-79 5 4
80-100 3 2
*Leadership position includes providers in charge of the facility or in charge of
the labor and delivery room
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Interviews with facility leaders, maternity heads, and
providers revealed facilitators and barriers to routine
uterotonic use during the third stage of labor (represen-
tative quotations shown in Table 4). Established facility
protocols, perception of prophylactic uterotonics as a
lifesaving drug, and a clear understanding of its indica-
tion facilitated routine administration. Several providers
reported that oxytocin supplied by the government was
both insufficient and inconsistently available at their fa-
cility; however, providers who perceived it as an essential
and lifesaving drug strongly encouraged patients and
their families to purchase oxytocin prior to giving birth.
Several providers – usually facility heads and experi-
enced midwives – reported using personal funds to pur-
chase oxytocin during government supply shortages.
The majority of these providers expressed being moti-
vated by an understanding that not providing prophylac-
tic uterotonics would be providing suboptimal care to a
Table 3 Relationship between provider characteristics and
reported routine administration of prophylactic uterotonics
Provider level
of training
Number (percentage) who
report routinely administered
prophylactic uterotonic
P < 0.05
MCHA 38/68 (56 %)
SECHN 18/34 (53 %)
Midwife 13/14 (93 %)
CHO/CHA 14/18 (78 %)
Total 83/134 (62 %)
Type of training P < 0.01
In service training 69/103 (67 %)
No in-service training 13/31 (42 %)
Table 4 Representative quotes regarding facilitators and barriers to the use of prophylactic uterotonics during the third stage of labor
Facilitators
Providers who understood the value of prophylactic uterotonics as a life saving drug purchased oxytocin when the government supply was
inconsistent.
• “Because oxy is an emergency drug it is very important for delivery. Sometime it is short, but I buy and keep it in the cupboard. Yea but
sometime government have shortage and don’t give us, but we buy.” – Clinical Health Officer
• “I want to save life, I’m not going to depend on government to give me oxy, so that’s why we usually buy it, whenever we have a case. “– Midwife
Established protocols in facility for preventing PPH
• “One of the protocols is that when the woman has delivered we give oxytocin.... All of this management is an attempt to prevent PPH.” – Clinical
Health Officer
Providers who understand the importance of oxytocin as a life saving drug strongly encouraged patients to purchase oxytocin when it was
unavailable
• “When we are short of oxytocin, we buy. If there is nothing, we tell them [patients], when they are term, birth preparedness, this will one of the
things that will be in the kit. You bring this, you bring this, and you bring this. The nurses write for them to bring. But normally it is around. For
those who can’t afford, we give. “– Clinical Health Officer
• “We ask them [patients], we force them to buy it because you know after delivery we need to help them with oxytocin.” – midwife
Providers purchase oxytocin out of fear of being audited
• “They order it so that we can save our own selves, because if you have a maternal death and you are on duty, they will query you. They will
judge you and you have to prove yourself, you have to take all of your documents and explain what happened and what did not happen. So
you will not allow that. So even if the midwife is not around, we have to take it out of [our own money].” – Maternal and Child Health Aid
Barriers
Providers reported giving uterotonics when it was available, but during shortages managed the third stage expectantly.
• “We give oxytocin if we have, but if we don’t have then we express normal procedures [expectant management].” – MCHA
Misconceptions about the universal indication of uterotonics – such as prolonged labor or if there is difficulty delivering placenta - prevented
providers from giving routinely
• “At times – we do not give oxytocin if the placenta comes out easily. There is no need to give oxytocin.”
• “Only when it is difficult labor we are told to give. But we haven’t had any yet.
Some providers report learning that uterotonics should be given to all patients but believe that it is not required unless the mother is bleeding
• “Well because we are supposed to give, but when we don’t have the case and we are not seeing enough profuse bleeding, I do not see
justification to give. So normally we do fundal massage for contractions to take place, and if there are clots then we expel. We check for tear,
perineal, cervical and we see how best – based on that if there is no profuse bleeding we don’t give.” – Clinical Health officer
Belief that prophylactic oxytocin is not needed if a patient delivers normally
• “After the delivery I didn’t give oxytocin because she delivered normally. Only if she is bleeding. Because some of them they deliver normally, no
problem.” – MCHA
• “After delivery I do not give any oxytocin because she delivered normally. Later on after 30–40 min {inaudible} so I had to set my normal saline
with 20 IU oxytocin and the woman was still bleeding so I called for sister to help me.” - MCHA
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patient. A very small number of providers also expressed
fear of being audited by the government in the case of a
poor maternal outcome as a driver to purchasing backup
supplies.
Barriers to the consistent use of prophylactic utero-
tonics included inconsistent supply and correct know-
ledge regarding proper indications for administration.
Providers expressed significant concern when oxytocin
was unavailable at their facility. Some providers reported
the use of uterotonics during the third stage of labor
when it was available, but resorted to expectant manage-
ment when the government supply of uterotonics was
unavailable and patients could not purchase it due to ei-
ther cost or access. Gaps in knowledge regarding the
proper indication and utility of prophylactic uterotonics
prevented providers from its routine administration.
Several providers expressed their belief that women who
underwent normal labor did not require prophylactic
uterotonics following delivery of the newborn. Other
providers specified that they would provide prophylactic
uterotonics if a patient’s labor was prolonged, there were
challenges delivering the placenta, or if there was any
bleeding during or immediately after delivery. Several
providers reported that they were taught both in their
traditional and in-service training to give prophylactic
uterotonics routinely to all women during the third stage
of labor, but they did not see a justification for this if a
woman was not bleeding, and therefore did not routinely
administer it.
Discussion
Our results showed that although there is a widespread
awareness, acceptance, and use of prophylactic utero-
tonics in Sierra Leone, there remains considerable room
for improvement. Of the134 providers surveyed, 62 %
reported routine use of uterotonics during the third
stage of labor. Although all health cadres are taught
AMTSL during pre-service training, those who received
in-service training including AMTSL were significantly
more likely to administer prophylactic uterotonics than
those who did not.
Providers in leadership positions such as CHOs and
midwives were also more likely to report uterotonic use
than providers who are frontline in conducting normal
uncomplicated deliveries (SECHNs and MCHAs). Ninety-
three percent of midwives and 77 % of CHOs/CHAs re-
ported routine use of uterotonics. These findings may
reflect differences in initial training or provider level of
experience. Unfortunately, providers with more experi-
ence such as midwives and CHOs/CHAs are more likely
to be involved after PPH has already developed, rather
than during the routine management of labor. This find-
ing, however, does represent a strong basis for transfer
of knowledge within a facility. Quality improvement
interventions focused on the active guideline develop-
ment by facility leaders – which has shown promise in
other settings – may play a role in increasing routine
uterotonic use [18].
Consistent provision of drugs is required for the timely
administration of any intervention. Although oxytocin is
an essential drug freely supplied by the Sierra Leone
government, providers cite that inadequate supply of
uterotonics remains a significant challenge to routine
administration. Our results showed that 39 % of facilities
had an inconsistent supply of oxytocin. Furthermore,
only one-third of facilities stored oxytocin within the
manufacturer-recommended temperature of 2–8°. Al-
though providers who perceived the value of oxytocin
purchased it with their own funds or strongly encour-
aged patients to do so, many providers reported that
oxytocin shortages contributed to their use of expectant
management of the third stage of labor. Limited avail-
ability of oxytocin in primary health facilities likely also
has implications for the emergent treatment of postpar-
tum hemorrhage. Further research is needed to assess
the efficacy of oxytocin in room temperature conditions
as well as the role of temperature independent utero-
tonics such as misoprostol in resource limited settings.
Study strengths and limitations
The major strength of this study is the location. Given
that Sierra Leone carries one of the highest maternal
mortality ratios worldwide, understanding provider prac-
tices of preventive interventions in peripheral health fa-
cilities where routine deliveries are encouraged serves as
a basis for targeted quality improvement. In addition,
few studies have documented specific provider percep-
tions that remain barriers to routine prophylactic utero-
tonic use. Limitations of this study include its descriptive
nature and small sample size. Interviews are subject to re-
call, and given desirability bias, providers may over-report
their use of oxytocin. Furthermore, this study did not as-
sess the timing of oxytocin administration. Given that
uterotonics are recommended within one minute after
delivery of the newborn, it is likely that observed deliv-
eries in these facilities would be less than optimal. Ob-
served studies conducted in high-volume hospitals have
indeed found a discrepancy between provider know-
ledge and timely administration of prophylactic utero-
tonics [19]. However, observing deliveries in peripheral
facilities with lower deliveries presents logistical and fi-
nancial challenges.
Conclusion
Despite evidence-based guidelines recommending the
use of prophylactic uterotonics during the third stage of
labor, hospitals in both developed and developing coun-
tries significantly underuse it. This study documents
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provider practices administering prophylactic uterotonics
in lower-level facilities in Sierra Leone, and provides insight
into several underlying reasons for its underutilization. Al-
though 67 % of providers who underwent in-service train-
ing reported the use of uterotonics, there still remains a
gap in optimal translation from in-service training to
knowledge retention and clinical practice. Other studies
have documented this, as well as the need for multiple
components in addition to dissemination of knowledge for
clinical behavior change to occur [11, 12]. Further research
is needed to determine the optimal duration, components,
and delivery of targeted AMTSL training.
Among the providers who did not routinely administer
uterotonics, supply of drugs, provider knowledge of
proper indication, and provider attitudes toward the util-
ity of prophylactic uterotonics were the most common
barriers to routine administration. For instance, several
providers described their belief that mothers who under-
went normal deliveries or did not have bleeding did not
require prophylactic uterotonics. This belief may lead to
sporadic use of prophylactic uterotonics, particularly in
the context of drug shortages. Professional and in-
service training presents an opportunity to emphasize
and reinforce the value of routine administration of
uterotonics even in normal deliveries.
There remains considerable room for quality improve-
ment in administering prophylactic uterotonics during
the third stage of labor. Although inconsistent supply of
uterotonics remains a barrier to routine use, accurate
provider knowledge regarding indications for and value
of prophylactic uterotonics also contribute to its
underutilization. Emphasis on incorporating and empha-
sizing the use of uterotonics during pre-service and in-
service training and the development of facility protocols
may improve practices. Consistent availability and imple-
mentation of oxytocin during the third stage of labor
represents a very simple, feasible, inexpensive interven-
tion to decrease bleeding postpartum, the most common
cause of maternal mortality worldwide.
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